• Tiziana initiates Phase 2a BANYAN trial of intranasal foralumab in patients with ALS

  Tiziana Life Sciences has announced the initiation of the Phase 2a Healey ALS MyMatch BANYAN trial of intranasal foralumab in people with amyotrophic lateral sclerosis. The company announced in November 2024 the ALS Association would… [Read more . . .]

• Kither Biotech initiates Phase 1b/2a trial of KIT2014 inhaled PDE3/4 inhibitor in COPD patients

  Kither Biotech has announced the initiation of a Phase 1b /2a study of KIT2014 inhaled PDE3/4 inhibitor in patients with COPD. The company recently announced results from a Phase 1 trial of KIT2014 in healthy… [Read more . . .]

• Harro Höfliger announces availability of commercial scale dry-filling technology for MDIs

  Harro Höfliger says that dry-filling technology for metered dose inhaler production, which has previously been available only at laboratory scale, is now available for commercial scale production lines. Dry filling, which Harro has developed in… [Read more . . .]

• Macquarie University research project on formulation of inhaled dry powder biologics will involve Aptar Pharma’s Orbital DPI

  Aptar Pharma has announced that its Orbital high-payload dry powder inhaler will be key to a Macquarie University research project titled “Unlocking the Potential of Dry Powder Carriers for Biologic Applications” which is funded by a… [Read more . . .]

• AstraZeneca’s Trixeo (Breztri) Aerosphere budesonide / glycopyrrolate / formoterol MDI approved by the EU for the treatment of asthma

  AstraZeneca announced that the European Commission has approved the company’s Trixeo (Breztri) Aerosphere budesonide / glycopyrrolate / formoterol MDI for the treatment of asthma in patients aged 12 and older whose asthma is not adequately… [Read more . . .]

• CF Pharmtech initiates Phase 1 trial of ICF004 antifibrotic DPI

• Polyrizon initiates trial of Nasarix (PL-14) intranasal allergen blocker for seasonal allergic rhinitis

• Bespak and Upperton team up to offer nasal drug development and manufacturing services

• FDA accepts Insmed’s sNDA to expand the use of Arikayce amikacin liposome inhalation suspension for MAC lung disease

• SpliSense initiates Phase 2b trial of SPL84 inhaled antisense oligonucleotide for the treatment of cystic fibrosis

More news . . .